Marta R. De Miguel

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.

Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.

Journal: AIDS (London, England)

Published: April 15, 2026

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 14, 2026

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: October 19, 2025

Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024).

Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024).

Journal: Open forum infectious diseases

Published: August 08, 2025

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 24, 2025

Preparing for the Next Physician's Visit: Usability and Validity of a Mobile Health App for People Living with HIV.

Preparing for the Next Physician's Visit: Usability and Validity of a Mobile Health App for People Living with HIV.

Journal: AIDS and behavior

Published: April 29, 2025

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Journal: The lancet. HIV

Published: February 18, 2025

Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023).

Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023).

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 27, 2025

Loneliness and social isolation in people with HIV aged ≥50 years. The No One Alone (NOA)-GeSIDA study conducted by the GeSIDA 12021 study group.

Loneliness and social isolation in people with HIV aged ≥50 years. The No One Alone (NOA)-GeSIDA study conducted by the GeSIDA 12021 study group.

Journal: HIV medicine

Published: April 04, 2024

Prospective study for the early detection of lung carcinoma in patients with HIV infection (GESIDA study 8815).

Prospective study for the early detection of lung carcinoma in patients with HIV infection (GESIDA study 8815).

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: January 25, 2024

Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.

Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.

Journal: Hepatology (Baltimore, Md.)

Published: October 20, 2023

Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.

Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: May 24, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026